Stemnion, Inc. is a privately held, cutting-edge biomedical company engaged in the research and development of unique amnion-derived multipotent progenitor cells for use in cell- and cell-product-based therapies. The Company’s focus is on regenerative medicine and cell transplantation therapies that may treat, and possibly cure, human diseases and injuries such as wounds, neurotrauma, spinal cord injury and diabetes. Stemnion is collaborating with major clinical research centers to advance these therapeutic applications.